This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Worried About a Weak Dollar? Here's How to Trade & Win
by Sanghamitra Saha
The ultra-easy Fed policy and widening U.S. deficit are likely to keep the greenback subdued in this coming days.
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.
Company News for June 1, 2020
by Zacks Equity Research
Companies in the news are: ADAP, BIG, YAMHF, CGNX
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy Stock
by Zacks Equity Research
Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Has Adaptimmune Therapeutics (ADAP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADAP) Outperforming Other Medical Stocks This Year?
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Adaptimmune Therapeutics plc (ADAP).
Top Ranked Momentum Stocks to Buy for January 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Buy Stock
by Zacks Equity Research
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
Athenex (ATNX) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Athenex (ATNX) shares rose nearly 7% in the last trading session, amid huge volumes.
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Radius Exceeds 2018 Financial Guidance, Provides Updates
by Zacks Equity Research
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
by Zacks Equity Research
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
Adaptimmune Therapeutics Worldwide Enters Oversold Territory
by Zacks Equity Research
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock
by Zacks Equity Research
Adaptimmune (ADAP) needs investors to pay close attention to the stock based on moves in the options market lately.
Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up
by Zacks Equity Research
Valeant (VRX) reported encouraging results for the third quarter but trimmed its guidance to reflect recent divestitures.
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
by Zacks Equity Research
Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
by Zacks Equity Research
Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.
Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3
by Zacks Equity Research
Mallinckrodt (MNK) sales and earnings declined in the third-quarter due to volume Acthar declines.
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
by Zacks Equity Research
Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.